Literature DB >> 10461613

Metabolic imaging and contractile reserve for assessment of myocardial viability: friends or foes?

J L Vanoverschelde, J A Melin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461613     DOI: 10.1016/s1071-3581(99)90012-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


× No keyword cloud information.
  48 in total

1.  Relation between contractile reserve and positron emission tomographic patterns of perfusion and glucose utilization in chronic ischemic left ventricular dysfunction: implications for identification of myocardial viability.

Authors:  P G Mélon; C M de Landsheere; C Degueldre; J L Peters; H E Kulbertus; L A Piérard
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

2.  Preoperative selection of patients with severely impaired left ventricular function for coronary revascularization. Role of low-dose dobutamine echocardiography and exercise-redistribution-reinjection thallium SPECT.

Authors:  J L Vanoverschelde; B L Gerber; A M D'Hondt; M De Kock; R Dion; W Wijns; J A Melin
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

3.  Prediction of improvement of regional left ventricular function after surgical revascularization. A comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography.

Authors:  M Arnese; J H Cornel; A Salustri; A Maat; A Elhendy; A E Reijs; F J Ten Cate; D Keane; A H Balk; J R Roelandt
Journal:  Circulation       Date:  1995-06-01       Impact factor: 29.690

4.  Evaluation of patterns of perfusion and metabolism in dobutamine-responsive myocardium.

Authors:  S Sawada; G Elsner; D S Segar; M O'Shaughnessy; S Khouri; J Foltz; P D Bourdillon; J R Bates; N Fineberg; T Ryan; G D Hutchins; H Feigenbaum
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

5.  Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction.

Authors:  D W Baker; R Jones; J Hodges; B M Massie; M A Konstam; E A Rose
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

6.  Assessment of viable myocardium by dobutamine transesophageal echocardiography and comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.

Authors:  F M Baer; E Voth; H J Deutsch; C A Schneider; H Schicha; U Sechtem
Journal:  J Am Coll Cardiol       Date:  1994-08       Impact factor: 24.094

7.  Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction.

Authors:  S C Smart; S Sawada; T Ryan; D Segar; L Atherton; K Berkovitz; P D Bourdillon; H Feigenbaum
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

Review 8.  A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina.

Authors:  S H Rahimtoola
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

9.  Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction.

Authors:  I Afridi; P A Grayburn; J A Panza; J K Oh; W A Zoghbi; T H Marwick
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

10.  Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans.

Authors:  C Depré; J L Vanoverschelde; J A Melin; M Borgers; A Bol; J Ausma; R Dion; W Wijns
Journal:  Am J Physiol       Date:  1995-03
View more
  1 in total

1.  Assessment of myocardial viability in patients with acute myocardial infarction by two-dimensional speckle tracking echocardiography combined with low-dose dobutamine stress echocardiography.

Authors:  Lei Gong; Dongye Li; Junhong Chen; Xiaoping Wang; Tongda Xu; Wenhua Li; Shaoyang Ren; Cheng Wang
Journal:  Int J Cardiovasc Imaging       Date:  2013-01-29       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.